Single answer
Is Alvotech (ALVO) a buy or sell?
4starter turns market data into one clear verdict you can act on.
Create a free account to save tickers and track your signals.
Log in to turn on watchlist alerts.
Decision snapshot
Everything you need to act fast, in one glance.
What is the conclusion?
Right now our advanced algorithms say:
Do analysts agree?
We compare consensus targets with today's price.
Consensus target for Alvotech is $8.60, which is $4.51 (110.27%) above the current price today's price.
Low target: $5.00 | High target: $10.00
Latest analyst updates
Recent rating and price target changes for this stock.
Company snapshot
A quick overview of the business and its public profile.
Alvotech through its subsidiaries develops and manufactures biosimilar medicines for patients worldwide It offers biosimilar products in the therapeutic areas of autoimmune eye and bone disorders as well as cancer The companys lead program is AVT02 a high concentration formulation biosimilar to Humira to treat various inflammatory conditions including rheumatoid arthritis psoriatic arthritis Crohns disease ulcerative colitis plaque psoriasis and other indications AVT04 a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis Crohns disease ulcerative colitis plaque psoriasis and other indications AVT06 a biosimilar to Eylea to treat various conditions such as agerelated macular degeneration macular edema and diabetic retinopathy and AVT03 a biosimilar to Xgeva and Prolia which is in the preclinical phase to treat prevent bone fracture spinal cord compression and the need for radiation or bone surgery in patients with certain types of cancer as well as prevent bone loss and increase bone mass It also offers AVT05 a biosimilar to Simponi and Simponi Aria which is in early phase development to treat various inflammatory conditions including rheumatoid arthritis psoriatic arthritis ulcerative colitis and other indications AVT16 a biosimilar to an immunology product AVT23 a biosimilar to Xolair which is in latestage development to treat nasal polyps and AVT33 a biosimilar to an oncology product The company was founded in 2013 and is headquartered in Reykjavik Iceland
Website: https://www.alvotech.com
Rates and inflation backdrop
US inflation for January 2026 was 0.17%. Over the last 12 months, inflation is 2.83%. The 10-year yield is 4.04 and is down -0.110 over the last 30 days.
Inflation sensitivity
Debt ratio: 0.91. Cash flow to debt ratio: -0.02. Net profit margin: 12.17%. Inflation risk score: medium (0.70/1).
Dividend history check
We cannot find any recorded dividends paid in our systems.
Trading liquidity
Yes, the average daily trading liquidity for Alvotech is $3M. You should therefore be able to get in and out of your positions relatively fast.
10-year return check
We cannot find data for Alvotech 10 years ago, but if you had invested on 2022-06-16 when the price was $11.19, you would have made a loss of $7.10 per share or 63.45%.
Why this answer
We combine price momentum, volatility, and trend signals to simplify the decision to one word.
Signal engine scans price, trend, and momentum indicators.
Targets and sentiment are checked against the live quote.
We keep the output simple: buy, sell, or hold.
Analyst consensus
How Wall Street targets compare to today's price.